Abstract
CCR5 (C-C chemokine receptor type 5) is a chemokine receptor that has been identified as a major HIV co-receptor in viral entry and therefore is a highly validated target for the development of new anti-HIV drugs. Here, we discuss the insights gained so far relevant to the development of small-molecule CCR5 inhibitors for the treatment of HIV, and highlight small-molecule CCR5 inhibitors that are currently under preclinical and clinical trials.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have